QUICK ANSWER
GLP-1 supplements fall into two categories: companion products for people already taking GLP-1 medications, and products claiming to naturally stimulate GLP-1 activity. Both face significant regulatory requirements. Without claims specifically substantiated for the product’s dose, formulation, and target population, brands in this category face real enforcement and litigation risk.
There are moments when a single pharmaceutical development reshapes an entire adjacent industry. The invention of statins changed how nutraceuticals marketed heart health. The rise of proton pump inhibitors opened a category for digestive supplements. And the GLP-1 drug phenomenon — Ozempic, Wegovy, Zepbound, and the expanding wave of semaglutide and tirzepatide products — is doing something similar to the supplement industry right now, but faster, louder, and with considerably more regulatory complexity attached.
The GLP-1 nutritional support market is projected to grow from $4.1 billion in 2025 to $13 billion by 2035. Hundreds of supplement brands have already pivoted to capture a share of it. Walk through any pharmacy or scroll any health retailer online and you’ll find products called “GLP-1 Support,” “Natural GLP-1 Booster,” and — most ambitiously — “Nature’s Ozempic.” The category has gone from niche to noisy in the space of roughly eighteen months.
And in the race to attach to one of the most commercially powerful drug categories in modern pharmaceutical history, most of these brands have created claims problems they haven’t yet realised they have.
Two Very Different Kinds of Product, One Confusing Category Name
The first thing worth understanding about “GLP-1 supplements” is that the label covers two fundamentally different value propositions — and the regulatory requirements for each are distinct.
The first category is companion supplements for people already taking GLP-1 drugs. GLP-1 drugs can lead to nutritional deficiencies and muscle loss, creating real demand for adjunct support — hydration solutions, protein supplements, functional foods to address side effects and maintain muscle mass.This is a legitimate, well-reasoned category. People on semaglutide are eating significantly less, losing muscle alongside fat, and experiencing digestive side effects including nausea and constipation. Protein supplements, creatine, electrolytes, probiotics — there’s a genuine clinical rationale for all of these in this context.
The second category is products claiming to replicate or stimulate GLP-1 activity in the body — the “natural Ozempic” positioning. These supplements don’t contain the synthetic hormone GLP-1. What they typically contain is a mix of natural ingredients like berberine, probiotics, psyllium,ginseng, and other botanical extracts — ingredients with varying degrees of evidence for metabolic effects. The implication — sometimes subtle, sometimes not — is that the product does something broadly comparable to a prescription GLP-1 drug, without the needle or the price tag.
Both categories are real. Both have commercial opportunity.But they have very different evidence requirements, very different regulatory risk profiles, and very different things they can legitimately say on a label.
The “Nature’s Ozempic” Problem
Berberine is the ingredient at the centre of this conversation. It’s a plant-derived compound with a genuine and reasonably well-studied metabolic evidence base — research has examined its effects on blood glucose, insulin sensitivity, and GLP-1 secretion from intestinal L-cells. When TikTok discovered it and dubbed it “nature’s Ozempic,” searches exploded and a hundred brands reformulated or relaunched around it overnight.
The problem is the gap between what the berberine evidence actually supports and what the cultural narrative around it implies. Available data suggest that berberine produces only modest weight reductions of approximately 2 to 4 kg, with many trials showing little to no effect compared to the approximately 10% weight loss observed with GLP-1 drug therapies. Most clinical trials have included fewer than 100 participants and were of short duration, often targeting glycemic or lipid outcomes rather than weight loss asa primary endpoint.
That’s a significant evidentiary gap between “has been studied for metabolic effects in small trials” and “comparable to Wegovy.” And it’s exactly the gap that creates regulatory exposure.
The FDA has issued only one supplement-related GLP-1 warning letter to date — to a brand making extreme weight-loss claims and stating its products were “better than Ozempic” and “FDA-approved.” Regulators have been largely quiet on the category so far. But quiet enforcement is not the same as permitted conduct. The FDA appears to be taking a relatively relaxed attitude toward GLP-1 supplement claims as long as they are properly framed as structure-function claims — the operative phrase being “properly framed.” The brands that get this wrong aren’t being warned in advance. They’re being warned after the fact, or named in class actions, or both.
The Substantiation Requirements Are More Specific Than Most Brands Realise
Even properly framed structure-function claims for GLP-1 support products carry substantiation requirements that go considerably beyond pointing to ingredient-level research.
A study demonstrating that an ingredient increases the body’sGLP-1 levels isn’t, on its own, enough to support a weight loss claim. And if the product claims to mitigate the side effects of GLP-1 drugs, the study population needs to include GLP-1 drug users. This is a point that trips up even careful brands. A berberine trial conducted in people with type 2 diabetes doesn’t automatically substantiate a claim made to people taking Ozempic for weight management. The population, the dose, and the outcome measure all need to map to the specific claim being made — not just the general ingredient territory. This is where a proper evidence strategy pays for itself.
In March 2026, the FDA issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1products. The enforcement momentum is clearly building. And while those warning letters targeted compounded pharmaceutical products rather than supplements,the regulatory logic — competent and reliable scientific evidence must support specific claims — applies equally to the supplement side of the market.
For brands in Australia, the picture is further complicated by the TGA’s listed medicines framework. Permitted indications for metabolic and weight management products are tightly defined. “Supports GLP-1 activity”doesn’t exist on the approved list. Claims need to map to what’s actually permitted — which in practice means talking about specific ingredients,specific mechanisms, and outcomes that sit within TGA-approved indication language, not borrowing the equity of a blockbuster pharmaceutical brand.
The Legitimate Opportunity Is Real — But It Requires Doing the Work
None of this means brands should stay out of the GLP-1 support category. The opportunity is genuine, the consumer need is real, and there’s a meaningful evidence base for several key ingredients when claims are matched carefully to what the research actually supports.
For companion supplement products — those genuinely designed to support people on GLP-1 medications — the clinical rationale is solid andthe claim territory is relatively navigable. Consider:
• Protein supplementation for muscle preservation
• Probiotics and fibre for digestive support
• Electrolytes for hydration management
• Micronutrient blends for nutritional gap-filling
These are specific, defensible, and increasingly well-evidenced for this specific population.
For products making broader metabolic or appetite claims, the bar is higher and the evidence required is more specific. The question every brand in this space should be asking isn’t “does berberine have evidence?” — it does — but rather: which specific outcome does our product’s formulation, atour specific dose, support in our specific target population? And do we have the research to back that specific claim, in that specific context, under the regulatory framework of each market we’re selling into?
The GLP-1 wave is one of the most significant commercial opportunities in the supplement category in a generation. The brands that navigate it successfully will be the ones who treated the evidence question seriously before the marketing question — not the ones who borrowed the most compelling pharmaceutical language and hoped nobody looked closely.
Frequently Asked Questions
What can a GLP-1 supplement legally claim?
In the US, properly framed structure-function claims are permitted — for example, claims about supporting metabolic health or appetite. Disease claims such as treating obesity or diabetes are not. In Australia, claims must map to TGA permitted indications for listed medicines. “Supports GLP-1 activity” is not an approved indication.
Is berberine the same asOzempic?
No. Berberine is a plant-derived compound studied for modest metabolic effects.Clinical data suggests it produces weight reductions of approximately 2–4 kg. GLP-1 drugs like semaglutide produce approximately 10–15% body weight reduction in clinical trials. The mechanisms, evidence bases, and regulatory status are fundamentally different.
What evidence does a GLP-1support supplement need?
The FTC requires competent and reliable scientific evidence that maps to the specific claim, dose, and target population. A study showing an ingredient raises GLP-1 levels is not sufficient on its own to support a weight loss claim. Studies must reflect the product’s actual formulation and the consumer it’s marketed to.
How is the TGA treatingGLP-1 supplement claims in Australia?
GLP-1 support is not a recognised permitted indication under the TGA’s listed medicines framework. Australian brands must map claims to approved indications— such as weight management support, metabolic health, or appetite regulation —and hold evidence substantiating those specific indications at time of listing.
What are the biggest claim risks for GLP-1 supplement brands?
The key risks are: implying equivalence to prescription GLP-1 drugs; using theOzempic or Wegovy name in marketing; making weight loss claims without population-specific substantiation; and using before-and-after imagery that implies drug-level results. The FDA issued 30 warning letters in March 2026 to telehealth companies for related violations.